Content about Bacterial vaginosis

May 1, 2013
Actavis to acquire rights to Valeant drug

Drug maker Actavis has acquired rights to a treatment for an experimental bacterial vaginosis from Valeant Pharmaceuticals International for about $55 million, the drug makers said.

PARSIPPANY, N.J. — Drug maker Actavis has acquired rights to a treatment for an experimental bacterial vaginosis from Valeant Pharmaceuticals International for about $55 million, the drug makers said Wednesday.

Actavis Specialty Brands' acquisition of Valeant's metronidazole vaginal gel is in the 1.3% strength. The deal includes an upfront payment, milestone payments and royalties for the first three years after the drug is commercialized. Actavis hopes to market the drug as early as the middle of next year.

January 31, 2013
Monistat survey: 75% of women experience yeast infections, but misconceptions persist

Research has shown that 3-in-4 women will experience candidiasis, more commonly known as a vaginal yeast infection, and 67% are embarrassed by it, Insight Pharmaceuticals announced, citing an independent survey commissioned for Monistat.

TREVOSE, Pa. — Research has shown that three in four women will experience candidiasis, more commonly known as a vaginal yeast infection, and 67% are embarrassed by it, Insight Pharmaceuticals announced Wednesday, citing an independent survey commissioned for Monistat.

March 8, 2010
Lake Consumer Products develops over-the-counter bacterial vaginosis treatment

Lake Consumer Products last week launched vH essentials BV treatment, a homeopathic vaginal tablet that...

JACKSON, Wis. Lake Consumer Products last week launched vH essentials BV treatment, a homeopathic vaginal tablet that provides relief from the odor, discharge and discomfort often associated with bacterial vaginosis.

According to the company, vH essentials BV treatment is the first over-the-counter BV symptom treatment product to be widely distributed through retail.